https://www.elusys.com/news/elusys-therapeutics-receives-health-canada-approval-for-anthim%C2%AE-for-the-treatment-of-inhalation-anthrax 2026-06-08 https://www.elusys.com/news/obiltoxaximab-receives-positive-chmp-opinion-for-the-treatment-of-inhalation-anthrax 2026-06-08 https://www.elusys.com/news/obiltoxaximab-receives-marketing-authorization-from-european-commission-for-the-treatment-of-inhalation-anthrax 2026-06-08 https://www.elusys.com/news/elusys-therapeutics-finalizes-hhs-contract-to-deliver-anthim%C2%AE%2C-its-treatment-for-inhalation-anthrax%2C-to-the-u.s.-department-of-health-and-human-services 2026-06-08 https://www.elusys.com/news/elusys-executes-initial-procurement-contract-to-deliver-anthim%C2%AE-to-the-canadian-government 2026-06-08 https://www.elusys.com/news/elusys-invited-to-present-lav-basta-48-anthrax-vaccine-at-the-annual-dtra-conference 2026-06-08 https://www.elusys.com/news/elusys-therapeutics-commends-u.s.-congress-for-introduction-of-h.r.-2707 2026-06-08